Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Thursday

Corbus Pharmaceuticals (NASDAQ:CRBP) will likely be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Corbus Pharmaceuticals to post earnings of ($1.80) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 9:00 AM ET.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, beating the consensus estimate of ($1.55) by $0.11. On average, analysts expect Corbus Pharmaceuticals to post $-4 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Corbus Pharmaceuticals Price Performance

Corbus Pharmaceuticals stock opened at $16.86 on Thursday. The firm has a 50 day simple moving average of $12.96 and a 200-day simple moving average of $9.74. Corbus Pharmaceuticals has a 1-year low of $4.64 and a 1-year high of $20.77. The stock has a market cap of $206.70 million, a price-to-earnings ratio of -3.54 and a beta of 2.84.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Benchmark reissued a “reduce” rating on shares of Corbus Pharmaceuticals in a research note on Monday, October 20th. Lifesci Capital raised shares of Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Saturday, July 12th. Oppenheimer lowered their price objective on shares of Corbus Pharmaceuticals from $56.00 to $53.00 and set an “outperform” rating for the company in a research report on Wednesday, August 6th. Piper Sandler reaffirmed an “overweight” rating and set a $51.00 price objective on shares of Corbus Pharmaceuticals in a research report on Monday, October 20th. Finally, B. Riley raised shares of Corbus Pharmaceuticals to a “strong-buy” rating and set a $28.00 price objective for the company in a research report on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Corbus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.00.

Insider Buying and Selling

In related news, CFO Sean F. Moran sold 12,981 shares of the stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $17.02, for a total transaction of $220,936.62. Following the completion of the transaction, the chief financial officer owned 73,313 shares of the company’s stock, valued at approximately $1,247,787.26. This trade represents a 15.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Yuval Cohen sold 18,660 shares of the stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $17.01, for a total transaction of $317,406.60. Following the sale, the chief executive officer owned 138,187 shares in the company, valued at approximately $2,350,560.87. This trade represents a 11.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 41,674 shares of company stock valued at $713,870 in the last ninety days. 3.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Corbus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new stake in Corbus Pharmaceuticals during the 1st quarter worth approximately $573,000. Bank of America Corp DE lifted its holdings in Corbus Pharmaceuticals by 333.6% during the 2nd quarter. Bank of America Corp DE now owns 71,893 shares of the biopharmaceutical company’s stock worth $496,000 after buying an additional 55,314 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Corbus Pharmaceuticals during the 2nd quarter worth approximately $137,000. 64.64% of the stock is currently owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.